Pimavanserin and Atypical Antipsychotics to Treat Parkinson Disease Psychosis
Episode 86, Apr 07, 2023, 10:00 AM
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with Dilesh Doshi, PharmD, vice president of Health Economic and Outcomes Research at Acadia Pharmaceuticals. He spoke on the advantages and benefits of pimavanserin (Nuplazid; Acadia), the only FDA-approved therapy to treat Parkinson disease psychosis. Additionally, he discussed recent data that compared efficacy and safety of other off-label therapies such as clozapine and quetiapine.
Looking for more Parkinson disease discussion? Check out the NeurologyLive® movement disorder clinical focus page.
Episode Breakdown:
In this episode, we spoke with Dilesh Doshi, PharmD, vice president of Health Economic and Outcomes Research at Acadia Pharmaceuticals. He spoke on the advantages and benefits of pimavanserin (Nuplazid; Acadia), the only FDA-approved therapy to treat Parkinson disease psychosis. Additionally, he discussed recent data that compared efficacy and safety of other off-label therapies such as clozapine and quetiapine.
Looking for more Parkinson disease discussion? Check out the NeurologyLive® movement disorder clinical focus page.
Episode Breakdown:
- 1:10 – Mechanistic differences between pimavanserin and other atypical antipsychotics
- 3:00 – Understanding drug-to-drug interactions for PDP
- 5:05 – Decision making with quetiapine and negative cognitive effects
- 7:10 – Improved use of pimavanserin since approval
- 9:00 – Neurology News Minute
- 11:40 – Potential predictors of mortality in Parkinson disease psychosis
- 15:20 – Possibility of preventing PD psychosis
- 17:20 – Future research on identifying subgroups of responders to treatment
This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
Tiziana Announces Planned Phase 2 Study of Foralumab in Progressive Multiple Sclerosis
Blarcamesine Deemed Safe, Effective in Phase 2 Extension Study of Parkinson Disease Dementia
Eplontersen Continues to Show Clinical Benefit in Long-Term Analysis of hATTR Polyneuropathy
- Reldesemtiv to be Discontinued in ALS Following Data Monitoring Committee Analysis
Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.